AU2012311428A1 - Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site - Google Patents

Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site Download PDF

Info

Publication number
AU2012311428A1
AU2012311428A1 AU2012311428A AU2012311428A AU2012311428A1 AU 2012311428 A1 AU2012311428 A1 AU 2012311428A1 AU 2012311428 A AU2012311428 A AU 2012311428A AU 2012311428 A AU2012311428 A AU 2012311428A AU 2012311428 A1 AU2012311428 A1 AU 2012311428A1
Authority
AU
Australia
Prior art keywords
peptide
arrangement
peptides
infection
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012311428A
Other languages
English (en)
Other versions
AU2012311428A2 (en
Inventor
Roland E. Kontermann
Udo Lorenz
Knut Ohlsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of AU2012311428A1 publication Critical patent/AU2012311428A1/en
Publication of AU2012311428A2 publication Critical patent/AU2012311428A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
AU2012311428A 2011-09-23 2012-09-21 Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site Abandoned AU2012311428A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11182598.0 2011-09-23
EP11182598 2011-09-23
US201161545763P 2011-10-11 2011-10-11
US61/545,763 2011-10-11
PCT/EP2012/068703 WO2013041707A1 (en) 2011-09-23 2012-09-21 Peptide or arrangement of peptides forming a staphylococcus aureus epitope binding site

Publications (2)

Publication Number Publication Date
AU2012311428A1 true AU2012311428A1 (en) 2014-04-24
AU2012311428A2 AU2012311428A2 (en) 2014-06-26

Family

ID=47913924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012311428A Abandoned AU2012311428A1 (en) 2011-09-23 2012-09-21 Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site

Country Status (6)

Country Link
US (1) US9422365B2 (https=)
EP (1) EP2758431A1 (https=)
JP (1) JP2014534169A (https=)
CN (1) CN103857697A (https=)
AU (1) AU2012311428A1 (https=)
WO (1) WO2013041707A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP3080160B1 (en) * 2013-12-13 2022-07-06 Rijksuniversiteit Groningen Antibodies against staphylococcus aureus and uses thereof
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) * 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) * 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
CN119431528B (zh) * 2024-10-28 2025-10-14 中国人民解放军陆军军医大学 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1377314E (pt) * 2001-01-26 2012-01-02 Inhibitex Inc Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções
JP2009031009A (ja) * 2007-07-24 2009-02-12 St Marianna Univ School Of Medicine 黄色ブドウ球菌の検出または同定方法および検出キット
MX2011012248A (es) 2009-05-18 2012-02-29 Univ Wuerzburg J Maximilians Anticuerpos o sus fragmentos dirigidos contra un epitope de staphylococcus aureus de isaa o isab.

Also Published As

Publication number Publication date
AU2012311428A2 (en) 2014-06-26
WO2013041707A1 (en) 2013-03-28
US20140234339A1 (en) 2014-08-21
CN103857697A (zh) 2014-06-11
JP2014534169A (ja) 2014-12-18
EP2758431A1 (en) 2014-07-30
US9422365B2 (en) 2016-08-23

Similar Documents

Publication Publication Date Title
US9422365B2 (en) Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site
CN103906535B (zh) 与葡萄球菌蛋白a的抗体相关的组合物和方法
Rouha et al. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody
KR102050267B1 (ko) 황색포도상구균 감염 및 연관된 질환을 치료하고 예방하는 방법
US9658230B2 (en) Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB
MXPA03011701A (es) Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.
JP2010513228A (ja) プロテインａ選択性を有する抗体
JP2008179634A (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
JP2010509937A (ja) プロテインａ選択性を有する抗体
TW202035443A (zh) 抗金黃色葡萄球菌抗體的組合
JP2010013454A (ja) グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体
WO2009137677A2 (en) Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
Pohanka Monoclonal and polyclonal antibodies production-preparation of potent biorecognition element
US20030228322A1 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
CN120943954A (zh) 抗金黄色葡萄球菌IsdB抗体的制备及其应用
Mwale et al. Antigenic epitopes on the outer membrane protein A of Escherichia coli identified with single-chain variable fragment (scFv) antibodies
Takauchi et al. The trans‐chromosomic mouse‐derived human monoclonal antibody promotes phagocytosis of Porphyromonas gingivalis by neutrophils
KR20170137111A (ko) 에스. 아우레우스의 면역글로불린 결합 단백질에 대해 지시된 항체
Camaione Biochemical characterization of a novel staphylococcal protein A (SpA) interaction with human fibronectin (Fn) and its role in Fn-dependent bacterial adhesion to host cells
Cui et al. A novel anti-PcrV monoclonal antibody inhibits toxin-mediated cytotoxicity and enhances survival in mouse models of Pseudomonas aeruginosa infection

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUN 2014

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application